Literature DB >> 21184040

[Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].

T Schmidt1, D A Tsakiris, M Grapow, M Siegemund.   

Abstract

Thrombotic microangiopathies are characterized by platelet activation, endothelial damage, hemolysis and microvascular occlusion. This group of diseases is primary represented by thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Patients present with microangiopathic hemolytic anemia and thrombocytopenia as well as occlusion-related organ ischemia to a variable degree. A deficiency of the metalloprotease ADAMTS-13 is a major risk for acute disease manifestation as this is a regulator of unusually large von Willebrand factor (vWF) multimers, which are extremely adhesive and secreted by endothelial cells. In classical TTP an ADAMTS-13 activity below 5% is specific, whereas in other forms of thrombotic microangiopathies activity of ADAMTS-13 ranges from very low to normal. Symptoms of different forms of thrombotic microangiopathy are frequently overlapping and a clear classification according to clinical criteria is often difficult. Due to a high mortality, particularly of TTP, immediate diagnosis and therapy are essential. In this article two cases of thombotic microangiopathy after cardiac surgery are reported. After exclusion of TTP and HUS as well as other etiologies of thrombotic microangiopathy a relationship between the use of extracorporeal circulation and the pathogenesis of thrombotic microangiopathy is assumed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184040     DOI: 10.1007/s00101-010-1819-2

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  22 in total

1.  Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery.

Authors:  P M Mannucci; A Parolari; M T Canciani; F Alemanni; M Camera
Journal:  J Thromb Haemost       Date:  2005-02       Impact factor: 5.824

2.  Thrombotic thrombocytopenic purpura: 2008 update.

Authors:  Mark A Crowther; James N George
Journal:  Cleve Clin J Med       Date:  2008-05       Impact factor: 2.321

3.  Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome.

Authors:  M Pavlovsky; R Weinstein
Journal:  J Clin Apher       Date:  1997       Impact factor: 2.821

4.  Thrombocytopenic purpura and platelet transfusion.

Authors:  S E Lind
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

Review 5.  Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents.

Authors:  A J Murgo
Journal:  Semin Hematol       Date:  1987-07       Impact factor: 3.851

6.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

7.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

8.  Postoperative thrombotic thrombocytopenic purpura following cardiovascular surgeries.

Authors:  J C Chang; A Shipstone; M A Llenado-Lee
Journal:  Am J Hematol       Date:  1996-09       Impact factor: 10.047

9.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Authors:  Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci
Journal:  Br J Haematol       Date:  2007-06-29       Impact factor: 6.998

10.  Further characterization of ADAMTS-13 inactivation by thrombin.

Authors:  J K Lam; C K N K Chion; S Zanardelli; D A Lane; J T B Crawley
Journal:  J Thromb Haemost       Date:  2007-03-12       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.